Wednesday, 26 August 2026European Markets

PORCELEYNE FLES Stock Bullish Momentum With A 9.52% Rise Today

Loading stream...

(VIANEWS) - The Market ended the session with PORCELEYNE FLES (PORF.AS) rising 9.52% to €11.50 on Thursday, after four sequential sessions in a row of losses. AEX-Index fell 0% to €759.17, after three sequential sessions in a row of losses, on what was a somewhat up trend trading session today.

About PORCELEYNE FLES

B.V. Delftsch Aardewerkfabriek ''De Porceleyne Fles Anno 1653'' produces and sells Delft Blue decorative pottery and modern pottery in the Netherlands. The company offers its products portfolio under the Royal Leerdam Crystal brand. B.V. Delftsch Aardewerkfabriek 'De Porceleyne Fles Anno 1653' was founded in 1653 and is based in Delft, the Netherlands.

Earnings Per Share

As for profitability, PORCELEYNE FLES has a trailing twelve months EPS of €0.49.

PE Ratio

PORCELEYNE FLES has a trailing twelve months price to earnings ratio of 23.47. Meaning, the purchaser of the share is investing €23.47 for every euro of annual earnings.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, PORCELEYNE FLES's stock is considered to be overbought (>=80).

More news about PORCELEYNE FLES (PORF.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com